Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients

David Joyce, Sheri Crow, Zhuo Li, Lyle Joyce, Carmelo Milano, Joseph Rogers, Nestor Villamizar-Ortiz, Dong Chen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

PURPOSE: A universal loss of von Willebrand factor (vWF) high-molecular-weight multimers (HMWM) has been demonstrated in continuous-flow left ventricular assist device (HeartMate II) recipients. However, no reliable clinical or laboratory predictors for an increased bleeding tendency in this patient population have been identified. This study evaluated the ability of a new automated latex particle-enhanced immunoturbidimetric vWF activity assay (ALPEIVA) to predict non-surgical bleeding risk in HeartMate II recipients. METHODS: As part of a prospective multicenter trial, pre-surgical, 7-day, and 30-day post-implantation blood samples were collected from 24 patients. ALPEIVA-assessed vWF activities were compared among patients with and without non-surgical bleeding complications after HeartMate II implantation. Additional laboratory testing included factor VIII activity (FVIII:C), vWF antigen (vWFAg), vWF ristocetin cofactor activity (vWF:RCo), and vWF multimer analysis. RESULTS: All 24 patients had HMWM losses after HeartMate II implantation. Five patients (20%) developed non-surgical bleeding complications between 14 days and 6 months after HeartMate II implantation. Among various laboratory variables, only mean ALPEIVA/vWFAg ratios (referred to as the "bleeding ratio") were significantly lower in patients with clinically relevant bleeding (mean, 0.70 ± 0.06) compared with patients without bleeding (mean, 0.78 ± 0.09; p = 0.02) when measured at 30 days. CONCLUSIONS: The post-surgical bleeding ratio could potentially predict non-surgical bleeding risk and guide anti-platelet and anti-coagulation strategies in HeartMate II recipients.

Original languageEnglish (US)
Pages (from-to)750-756
Number of pages7
JournalJournal of Heart and Lung Transplantation
Volume31
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Heart-Assist Devices
von Willebrand Factor
Hemorrhage
Microspheres
Molecular Weight
Statistical Factor Analysis
Multicenter Studies
Weight Loss
Blood Platelets
Antigens

Keywords

  • axial flow
  • bleeding complications
  • heart failure
  • high molecular weight von Willebrand factor multimers
  • left ventricular assist device

ASJC Scopus subject areas

  • Transplantation
  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine
  • Surgery

Cite this

Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients. / Joyce, David; Crow, Sheri; Li, Zhuo; Joyce, Lyle; Milano, Carmelo; Rogers, Joseph; Villamizar-Ortiz, Nestor; Chen, Dong.

In: Journal of Heart and Lung Transplantation, Vol. 31, No. 7, 07.2012, p. 750-756.

Research output: Contribution to journalArticle

Joyce, D, Crow, S, Li, Z, Joyce, L, Milano, C, Rogers, J, Villamizar-Ortiz, N & Chen, D 2012, 'Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients', Journal of Heart and Lung Transplantation, vol. 31, no. 7, pp. 750-756. https://doi.org/10.1016/j.healun.2012.02.032
Joyce, David ; Crow, Sheri ; Li, Zhuo ; Joyce, Lyle ; Milano, Carmelo ; Rogers, Joseph ; Villamizar-Ortiz, Nestor ; Chen, Dong. / Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients. In: Journal of Heart and Lung Transplantation. 2012 ; Vol. 31, No. 7. pp. 750-756.
@article{4d2910be2f654d9a816169093c2042b7,
title = "Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients",
abstract = "PURPOSE: A universal loss of von Willebrand factor (vWF) high-molecular-weight multimers (HMWM) has been demonstrated in continuous-flow left ventricular assist device (HeartMate II) recipients. However, no reliable clinical or laboratory predictors for an increased bleeding tendency in this patient population have been identified. This study evaluated the ability of a new automated latex particle-enhanced immunoturbidimetric vWF activity assay (ALPEIVA) to predict non-surgical bleeding risk in HeartMate II recipients. METHODS: As part of a prospective multicenter trial, pre-surgical, 7-day, and 30-day post-implantation blood samples were collected from 24 patients. ALPEIVA-assessed vWF activities were compared among patients with and without non-surgical bleeding complications after HeartMate II implantation. Additional laboratory testing included factor VIII activity (FVIII:C), vWF antigen (vWFAg), vWF ristocetin cofactor activity (vWF:RCo), and vWF multimer analysis. RESULTS: All 24 patients had HMWM losses after HeartMate II implantation. Five patients (20{\%}) developed non-surgical bleeding complications between 14 days and 6 months after HeartMate II implantation. Among various laboratory variables, only mean ALPEIVA/vWFAg ratios (referred to as the {"}bleeding ratio{"}) were significantly lower in patients with clinically relevant bleeding (mean, 0.70 ± 0.06) compared with patients without bleeding (mean, 0.78 ± 0.09; p = 0.02) when measured at 30 days. CONCLUSIONS: The post-surgical bleeding ratio could potentially predict non-surgical bleeding risk and guide anti-platelet and anti-coagulation strategies in HeartMate II recipients.",
keywords = "axial flow, bleeding complications, heart failure, high molecular weight von Willebrand factor multimers, left ventricular assist device",
author = "David Joyce and Sheri Crow and Zhuo Li and Lyle Joyce and Carmelo Milano and Joseph Rogers and Nestor Villamizar-Ortiz and Dong Chen",
year = "2012",
month = "7",
doi = "10.1016/j.healun.2012.02.032",
language = "English (US)",
volume = "31",
pages = "750--756",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients

AU - Joyce, David

AU - Crow, Sheri

AU - Li, Zhuo

AU - Joyce, Lyle

AU - Milano, Carmelo

AU - Rogers, Joseph

AU - Villamizar-Ortiz, Nestor

AU - Chen, Dong

PY - 2012/7

Y1 - 2012/7

N2 - PURPOSE: A universal loss of von Willebrand factor (vWF) high-molecular-weight multimers (HMWM) has been demonstrated in continuous-flow left ventricular assist device (HeartMate II) recipients. However, no reliable clinical or laboratory predictors for an increased bleeding tendency in this patient population have been identified. This study evaluated the ability of a new automated latex particle-enhanced immunoturbidimetric vWF activity assay (ALPEIVA) to predict non-surgical bleeding risk in HeartMate II recipients. METHODS: As part of a prospective multicenter trial, pre-surgical, 7-day, and 30-day post-implantation blood samples were collected from 24 patients. ALPEIVA-assessed vWF activities were compared among patients with and without non-surgical bleeding complications after HeartMate II implantation. Additional laboratory testing included factor VIII activity (FVIII:C), vWF antigen (vWFAg), vWF ristocetin cofactor activity (vWF:RCo), and vWF multimer analysis. RESULTS: All 24 patients had HMWM losses after HeartMate II implantation. Five patients (20%) developed non-surgical bleeding complications between 14 days and 6 months after HeartMate II implantation. Among various laboratory variables, only mean ALPEIVA/vWFAg ratios (referred to as the "bleeding ratio") were significantly lower in patients with clinically relevant bleeding (mean, 0.70 ± 0.06) compared with patients without bleeding (mean, 0.78 ± 0.09; p = 0.02) when measured at 30 days. CONCLUSIONS: The post-surgical bleeding ratio could potentially predict non-surgical bleeding risk and guide anti-platelet and anti-coagulation strategies in HeartMate II recipients.

AB - PURPOSE: A universal loss of von Willebrand factor (vWF) high-molecular-weight multimers (HMWM) has been demonstrated in continuous-flow left ventricular assist device (HeartMate II) recipients. However, no reliable clinical or laboratory predictors for an increased bleeding tendency in this patient population have been identified. This study evaluated the ability of a new automated latex particle-enhanced immunoturbidimetric vWF activity assay (ALPEIVA) to predict non-surgical bleeding risk in HeartMate II recipients. METHODS: As part of a prospective multicenter trial, pre-surgical, 7-day, and 30-day post-implantation blood samples were collected from 24 patients. ALPEIVA-assessed vWF activities were compared among patients with and without non-surgical bleeding complications after HeartMate II implantation. Additional laboratory testing included factor VIII activity (FVIII:C), vWF antigen (vWFAg), vWF ristocetin cofactor activity (vWF:RCo), and vWF multimer analysis. RESULTS: All 24 patients had HMWM losses after HeartMate II implantation. Five patients (20%) developed non-surgical bleeding complications between 14 days and 6 months after HeartMate II implantation. Among various laboratory variables, only mean ALPEIVA/vWFAg ratios (referred to as the "bleeding ratio") were significantly lower in patients with clinically relevant bleeding (mean, 0.70 ± 0.06) compared with patients without bleeding (mean, 0.78 ± 0.09; p = 0.02) when measured at 30 days. CONCLUSIONS: The post-surgical bleeding ratio could potentially predict non-surgical bleeding risk and guide anti-platelet and anti-coagulation strategies in HeartMate II recipients.

KW - axial flow

KW - bleeding complications

KW - heart failure

KW - high molecular weight von Willebrand factor multimers

KW - left ventricular assist device

UR - http://www.scopus.com/inward/record.url?scp=84861880734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861880734&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2012.02.032

DO - 10.1016/j.healun.2012.02.032

M3 - Article

VL - 31

SP - 750

EP - 756

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 7

ER -